The positive results from REV technology have induced the pharma company to actively participate in the testing program, which aims to refine the processes and seek FDA approval for the entire procedure.
EnWave Co-CEO Tim Durance said the pharmaceutical company is expected to make a major breakthrough in the global pharmaceutical industry.
"If REV can successfully contribute to their proprietary process, EnWave will be positioned well to benefit from their potential success,” Durance added.
”This collaboration will also provide the opportunity to get the REV method FDA exposure and possible approval."
EnWave’s dehydration technology portfolio for pharmaceuticals and biomaterials includes freezeREV, powderREV and bioREV, each using a combination of microwave energy with a low pressure environment to achieve controlled dehydration of live or active biological materials.